open access

Vol 23, No 1 (2016)
Original articles
Published online: 2015-06-19
Get Citation

Serum copeptin level can be a helpful biomarker in evaluation of myocardial perfusion scintigraphy results

Hüseyin Ede, Seyhan Karaçavuş, Ayşe Yeşim Göçmen, Barış Yaylak, Süleyman Akkaya, Burak Açıkgöz, Neslihan Çilek, Mahmut Kılıç, Ali Rıza Erbay
DOI: 10.5603/CJ.a2015.0036
·
Pubmed: 26100831
·
Cardiol J 2016;23(1):71-77.

open access

Vol 23, No 1 (2016)
Original articles
Published online: 2015-06-19

Abstract

Background: Myocardial perfusion scintigraphy (MPS) is a well-established diagnostic tool. The sensitivity and specificity of single photon emission computed tomography (SPECT) MPS to detect significant coronary lesion were 86% and 74%, respectively. The aim of this study was to examine the role of serum copeptin in evaluation of MPS.

Methods: Sixty-two consecutive patients underwent both SPECT MPS using 99mTc-sestamibi and transthoracic echocardiography were enrolled prospectively. Age, gender, height, weight, presence of cardiovascular risk factors were recorded. Exercise treadmill test (ETT) with modified Bruce protocol was used to induce coronary ischemia during MPS. While performing MPS, blood samples for serum copeptin level were drawn three times at pre-exercise, at the peak of ETT, and 6 h after ETT, respectively. The patients were enrolled into three groups according to MPS results (normal, equivocal and ischemia).

Results: The study included 62 patients (23 with normal, 20 with equivocal, 19 with ischemia on MPS). Pre-, peak-, and post-exercise B-type natriuretic peptide and troponin I values were similar across the groups (p > 0.05 for all comparisons). Serum copeptin values for pre- and peak-exercise were similar among all groups (p = 0.883 and p = 0.089). Post-exercise copeptin values of the normal and equivocal groups were similar (p = 0.661, z = –0.438) while that of the ischemia group was significantly higher than both the normal (p < 0.001) and equivocal group (p < 0.001).

Conclusions: Serum copeptin was found to be increasing significantly in case of ischemia on MPS. It may be used in differentiation of equivocal results from false positive results.  

Abstract

Background: Myocardial perfusion scintigraphy (MPS) is a well-established diagnostic tool. The sensitivity and specificity of single photon emission computed tomography (SPECT) MPS to detect significant coronary lesion were 86% and 74%, respectively. The aim of this study was to examine the role of serum copeptin in evaluation of MPS.

Methods: Sixty-two consecutive patients underwent both SPECT MPS using 99mTc-sestamibi and transthoracic echocardiography were enrolled prospectively. Age, gender, height, weight, presence of cardiovascular risk factors were recorded. Exercise treadmill test (ETT) with modified Bruce protocol was used to induce coronary ischemia during MPS. While performing MPS, blood samples for serum copeptin level were drawn three times at pre-exercise, at the peak of ETT, and 6 h after ETT, respectively. The patients were enrolled into three groups according to MPS results (normal, equivocal and ischemia).

Results: The study included 62 patients (23 with normal, 20 with equivocal, 19 with ischemia on MPS). Pre-, peak-, and post-exercise B-type natriuretic peptide and troponin I values were similar across the groups (p > 0.05 for all comparisons). Serum copeptin values for pre- and peak-exercise were similar among all groups (p = 0.883 and p = 0.089). Post-exercise copeptin values of the normal and equivocal groups were similar (p = 0.661, z = –0.438) while that of the ischemia group was significantly higher than both the normal (p < 0.001) and equivocal group (p < 0.001).

Conclusions: Serum copeptin was found to be increasing significantly in case of ischemia on MPS. It may be used in differentiation of equivocal results from false positive results.  

Get Citation

Keywords

copeptin, myocardial perfusion scintigraphy, coronary artery disease, ischemia

About this article
Title

Serum copeptin level can be a helpful biomarker in evaluation of myocardial perfusion scintigraphy results

Journal

Cardiology Journal

Issue

Vol 23, No 1 (2016)

Pages

71-77

Published online

2015-06-19

DOI

10.5603/CJ.a2015.0036

Pubmed

26100831

Bibliographic record

Cardiol J 2016;23(1):71-77.

Keywords

copeptin
myocardial perfusion scintigraphy
coronary artery disease
ischemia

Authors

Hüseyin Ede
Seyhan Karaçavuş
Ayşe Yeşim Göçmen
Barış Yaylak
Süleyman Akkaya
Burak Açıkgöz
Neslihan Çilek
Mahmut Kılıç
Ali Rıza Erbay

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl